Pre-made Lenzilumab biosimilar ( Whole mAb, anti-CSF2 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-303
Anti-CSF2 therapeutic antibody (Pre-made Lenzilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Lenzilumab (INN; development code KB003) is a humanized monoclonal antibody (class IgG1 kappa) that targets colony stimulating factor 2 (CSF2)/granulocyte-macrophage colony stimulating factor (GM-CSF).
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CSF2 therapeutic antibody (Pre-made Lenzilumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||COVID-19;Cytokine release syndrome;B-cell lymphoma;Drug hypersensitivity;Precursor cell lymphoblastic leukaemia-lymphoma;Graft-versus-host disease|
|Conditions Discontinued||Asthma;Rheumatoid arthritis;Chronic myelomonocytic leukaemia;Solid tumours|
|Development Tech||Humaneering Technology|